Anti-p53 autoantibody in colorectal cancer: Prognostic significance in long-term follow-up

International Journal of Colorectal Disease

Volumn 23, Issue 6, 2008, Pages 595-600

  Suppiah, A ^a   Alabi, A ^a   Madden, L ^a   Hartley, J E ^a   Monson, J R T ^a   Greenman, J ^a  

^a UNIVERSITY OF HULL   (United Kingdom)

Author keywords

Anti p53 autoantibody; Colorectal Cancer; p53; Prognosis

Indexed keywords

AUTOANTIBODY; FLUOROURACIL; PROTEIN P53;

ADJUVANT THERAPY; ADULT; AGED; ARTICLE; BLOOD ANALYSIS; CANCER CLASSIFICATION; CANCER STAGING; COLORECTAL CANCER; COLORECTAL SURGERY; CONTROLLED STUDY; DISEASE FREE SURVIVAL; ENZYME LINKED IMMUNOSORBENT ASSAY; FEMALE; FOLLOW UP; HUMAN; HUMAN TISSUE; LIVER METASTASIS; LUNG METASTASIS; MAJOR CLINICAL STUDY; MALE; MULTIVARIATE ANALYSIS; OVERALL SURVIVAL; PRIORITY JOURNAL; PROGNOSIS; TUMOR LOCALIZATION;

AGED; AUTOANTIBODIES; COLORECTAL NEOPLASMS; ENZYME-LINKED IMMUNOSORBENT ASSAY; FEMALE; HUMANS; MALE; MIDDLE AGED; PROGNOSIS; SURVIVAL RATE; TUMOR MARKERS, BIOLOGICAL; TUMOR SUPPRESSOR PROTEIN P53;

EID: 41949092935     PISSN: 01791958     EISSN: None     Source Type: Journal    
DOI: 10.1007/s00384-008-0458-4     Document Type: Article

References (18)

1. Crawford LV, Pim DC, Bulbrook RD (1982) Detection of antibodies against the cellular protein p53 in sera from patients with breast cancer. Int J Cancer 30:403-408
2. Soussi T (2000) p53 Antibodies in the sera of patients with various types of cancer: A review. Cancer Res 60:1777-1788
3. Tang R, Ko MC, Wang JY, Changchien CR, Chen HH, Chen JS, Hsu KC, Chiang JM, Hsieh LL (2001) Humoral response to p53 in human colorectal tumors: a prospective study of 1,209 patients. Int J Cancer 94:859-863
4. Kressner U, Inganas M, Byding S, Blikstad I, Pahlman L, Glimelius B, Lindmark G (1997) Prognostic value of p53 genetic changes in colorectal cancer. J Clin Oncol 17:593-599
5. Soong R, Powell B, Elsaleh H, Gnanasampanthan G, Smith DR, Goh HS, Joseph D, Iacopetta B (2000) Prognostic significance of TP53 gene mutation in 995 cases of colorectal carcinoma. Influence of tumour site, stage, adjuvant chemotherapy and type of mutation. Eur J Cancer 36:2053-2060
6. Houbiers JG, van der Burg SH, van de Watering LM, Tollenaar RA, Brand A, van de Velde CJ, Melief CJ (1995) Antibodies against p53 are associated with poor prognosis of colorectal cancer. Br J Cancer 72:637-641
7. Kressner U, Glimelius B, Bergstrom R, Pahlman L, Larsson A, Lindmark G (1998) Increased serum p53 antibody levels indicate poor prognosis in patients with colorectal cancer. Br J Cancer 77:1848-1851
8. Shiota G, Ishida M, Noguchi N, Oyama K, Takano Y, Okubo M, Katayama S, Tomie Y, Harada K, Hori K, Ashida K, Kishimoto Y, Hosoda A, Suou T, Kanbe T, Tanaka K, Nosaka K, Tanida O, Kojo H, Miura K, Ito H, Kaibara N, Kawasaki H (2000) Circulating p53 antibody in patients with colorectal cancer: Relation to clinicopathologic features and survival. Dig Dis Sci 45:122-128
9. Angelopoulou K, Diamandis EP, Sutherland DJ, Kellen JA, Bunting PS (1994) Prevalence of serum antibodies against the p53 tumor suppressor gene protein in various cancers. Int J Cancer 58:480-487
10. Angelopoulou K, Stratis M, Diamandis EP (1997) Humoral immune response against p53 protein in patients with colorectal carcinoma. Int J Cancer 70:46-51
11. Takeda A, Shimada H, Nakajima K, Yoshimura S, Suzuki T, Asano T, Ochiai T, Isono K (2001) Serum p53 antibody as a useful marker for monitoring of treatment of superficial colorectal adenocarcinoma after endoscopic resection. Int J Clin Oncol 6:45-49
12. Shibata Y, Kotanagi H, Andoh H, Koyama K, Itoh H, Kudo S (1996) Detection of circulating anti-p53 antibodies in patients with colorectal carcinoma and the antibody's relation to clinical factors. Dis Colon Rectum 39:1269-1274
13. Bielicki D, Karbowniczek M, Sulzyc-Bielicka V, Kladny J, Boer C, Marlicz K, Domagala W (1999) Clinico-pathological characteristics of colorectal cancer and serum anti-p53 antibodies. Pol J Pathol 50:77-81
14. Chang SC, Lin JK, Lin TC, Liang WY (2005) Genetic alteration of p53, but not overexpression of intratumoral p53 protein, or serum p53 antibody is a prognostic factor in sporadic colorectal adenocarcinoma. Int J Oncol 26:65-75
15. Lechpammer M, Lukac J, Lechpammer S, Kovacevic D, Loda M, Kusic Z (2004) Humoral immune response to p53 correlates with clinical course in colorectal cancer patients during adjuvant chemotherapy. Int J Colorectal Dis 19:114-120
16. Broll R, Duchrow M, Oevermann E, Wellm C, Schwandner O, Schimmelpenning H, Roblick UJ, Bruch HP, Windhovel U (2001) p53 autoantibodies in sera of patients with a colorectal cancer and their association to p53 protein concentration and p53 immunohistochemistry in tumor tissue. Int J Colorectal Dis 16:22-27
17. Shimada H, Ochiai T, Nomura F (2003) Titration of serum p53 antibodies in 1,085 patients with various types of malignant tumors: A multiinstitutional analysis by the Japan p53 Antibody Research Group. Cancer 97:682-689
18. Hammel P, Boissier B, Chaumette MT, Piedbois P, Rotman N, Kouyoumdjian JC, Lubin R, Delchier JC, Soussi T (1997) Detection and monitoring of serum p53 antibodies in patients with colorectal cancer. Gut 40:356-361